Quarterly report pursuant to Section 13 or 15(d)

Condensed Balance Sheets

v2.4.0.6
Condensed Balance Sheets (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Dec. 31, 2011
Current assets:    
Cash $ 5,062 $ 5,406
Receivables 3,530 3,720
Prepaid expenses and other current assets 788 836
Total current assets 9,380 9,962
Property and equipment, net 1,364 255
Total assets 10,744 10,217
Current liabilities:    
Accounts payable 4,878 4,789
Accrued clinical trials expenses 650 161
Other accrued liabilities 234 173
Deferred revenue 1,700   
Warrant liability, current 931   
Current portion of long-term debt, net of discount 2,500   
Total current liabilities 10,893 5,123
Warrant liabilities 7,277 3,611
Royalty liability 10,087 9,309
Long-term debt, net of discount 9,618 12,253
Total liabilities 37,875 30,296
Commitments and contingencies      
Stockholders' deficit:    
Common stock, at amounts paid-in 262,052 256,436
Additional paid-in capital 20,666 18,433
Accumulated deficit (309,849) (294,948)
Total stockholders' deficit (27,131) (20,079)
Total liabilities and stockholders' deficit $ 10,744 $ 10,217